Rezdiffra (Resmetirom) Effect on GGT: What the Trial Data Shows

What GGT Can and Cannot Tell You

Gamma-glutamyl transferase (GGT) may be included in a liver-test panel, but it is nonspecific. A result can be influenced by liver and biliary conditions, alcohol exposure, medicines, and other factors. A lower result is not proof that MASH has resolved; a higher result is not, by itself, proof of drug injury, treatment failure, alcohol use, or obstruction [1].

Resmetirom’s phase 3 trial evaluated clinical and histologic outcomes in people with MASH and fibrosis, not a personal GGT target that every patient should reach [2]. Trial averages and subgroup results do not create a threshold for a particular person. A clinician may use laboratory trends with symptoms, other liver tests, imaging, medical history, and the indication for treatment.

What the Current Label Requires

FDA-approved labeling is the appropriate primary source for practical safety information. The Rezdiffra label describes warnings and precautions, including hepatotoxicity and gallbladder-related adverse reactions, and asks prescribers to monitor for symptoms and liver-test changes consistent with liver injury [3]. It also contains interaction and dose-adjustment information that depends on concomitant medicines and hepatic status.

That is different from a web-derived schedule to draw GGT at fixed weeks or to change treatment when an isolated number moves. The label and prescribing clinician, not an article, should direct monitoring and any decision to start, stop, or change therapy. A person who develops concerning symptoms such as jaundice, worsening abdominal pain, fever, vomiting, or unusual fatigue should contact the care team promptly.

Interpreting a Change Safely

An isolated laboratory change is not diagnostic of treatment response or injury. A prescriber may consider the full pattern of results, symptoms, medication changes, alcohol exposure, intercurrent illness, and other possible explanations. This is particularly important because people taking resmetirom may also use lipid-lowering medicines or other treatments that require medication reconciliation.

Do not compare GGT reductions across unrelated trials to rank treatments. Differences in population, baseline values, duration, definitions, and study design make cross-trial percentages unreliable. Likewise, a normal GGT does not establish histologic resolution, and an abnormal GGT does not stage fibrosis. Noninvasive tests and other assessments have their own limits and should be selected by the care team [1].

Bottom Line

The evidence supports a narrow conclusion: GGT can be one piece of liver follow-up, but it cannot independently diagnose MASH, establish a resmetirom response, or substitute for clinical assessment. Follow the current Rezdiffra label and the plan created by the prescribing clinician rather than using a fixed online GGT protocol.